Scancell Holdings plc
SCNLF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.46B
Close$
$-0.15
110.8% downside
Current Fair Value
110.8% downsideOvervalued by 110.8% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $1.46 Billion |
|---|---|
| Enterprise Value | - |
| Earnings per Share | $-0.01 |
| Beta | 0.74 |
| Outstanding Shares | 1,037,406,403 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -17.55 |
|---|---|
| PEG | 0.33 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Last Earnings Call
Report Date
October 23, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
February 4, 2027
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Scancell Holdings plc
60 employees
CEO: Phillip John L'Huillier
Scancell Holdings plc is a clinical-stage biopharmaceutical firm focused on discovering and developing innovative vaccine and antibody treatments. Its mission is to address significant unmet medical needs in both cancer and infectious di...